With this in mind, Lamberg and colleagues sought to examine the risk of another cardiovascular disease—venous thromboembolism (VTE)—in patients treated with bisphosphonates. The investigators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback